ExonHit Therapeutics Inc. is Beneficiary of a Grant from the European Union Within the Responsify Consortium  
3/5/2012 10:09:13 AM

PARIS--(BUSINESS WIRE)--Regulatory News:

€ 418,000 grant European personalized medicine consortium with 12 partners Identification of predictive biomarkers of response to two treatments of breast cancer

Exonhit (Paris:ALEHT) announced today that it is the beneficiary of a €418,000 grant from the European Union through its participation in the RESPONSIFY consortium financed under the 7th Framework Programme for Research and Technological Development (FP7) set up by the European Commission to co-finance research and development projects with grants to research actors.